Arena Pharmaceuticals (United States)

Recent papers from Arena Pharmaceuticals (United States)

1. Conformal risk control for non-monotonic lossesPhilosophical Transactions of the Royal Society A Mathematical Physical and Engineering Sciences · 2026
2. Uterine Leiomyomas Presenting During Pregnancy and DeliveryThe American Journal of Surgical Pathology · 2026
3. Targeting Pediatric Glioblastomas by Combining OLIG2 Inhibitor CT-179 with Fractionated Radiation in a Panel of Patient-Derived Orthotopic Xenograft Mouse ModelsInternational Journal of Molecular Sciences · 2026
4. Drug and single-cell gene expression integration identifies sensitive and resistant glioblastoma cell populationsNature Communications · 2026
5. Drug and Single-Cell Gene Expression Integration Identifies Sensitive and Resistant Glioblastoma Cell Populations2025
6. Diazepine Agonists of the 5-HT2C Receptor with Unprecedented Selectivity: Discovery of Bexicaserin (LP352)Journal of Medicinal Chemistry · 2025
7. S1PR4-dependent effects of Etrasimod on primary human myeloid immune cell activationFrontiers in Pharmacology · 2025
8. Azenosertib Is a Potent and Selective WEE1 Kinase Inhibitor with Broad Antitumor Activity Across a Range of Solid TumorsMolecular Cancer Therapeutics · 2025
9. Unique pharmacological properties of etrasimod among S1P receptor modulatorsFEBS Open Bio · 2024
10. 2022 County-Level Population Changes in the United States Through the Lens of the Lifestyle Health IndexJournal of Cardiopulmonary Rehabilitation and Prevention · 2024
11. Cardiovascular Evaluation of Etrasimod, a Selective Sphingosine 1‐phosphate Receptor Modulator, in Healthy Adults: Results of a Randomized, Thorough QT/QTc StudyClinical Pharmacology in Drug Development · 2024
12. Safety, Pharmacokinetics, and Pharmacodynamics of Etrasimod: Single and Multiple Ascending Dose Studies in Healthy AdultsClinical Pharmacology in Drug Development · 2024
13. Introducing the Lifestyle Health Index in the American NationsJournal of Cardiopulmonary Rehabilitation and Prevention · 2024
14. GPU Acceleration of a Conjugate Exponential Model for Cancer Tissue HeterogeneityACM Transactions on Computing for Healthcare · 2024
15. Achievement of Clinical, Endoscopic, and Histological Outcomes in Patients with Ulcerative Colitis Treated with Etrasimod, and Association with Faecal Calprotectin and C-reactive Protein: Results From the Phase 2 OASIS TrialJournal of Crohn s and Colitis · 2024
16. Patients with Acute Severe Ulcerative Colitis Treated with IV Cyclosporine Who Require Colectomy Within 3 Months of Discharge Have Lower Serum Cyclosporine Levels2024
17. Disposition and Mass Balance of Etrasimod in Healthy Subjects and In Vitro Determination of the Enzymes Responsible for Its Oxidative MetabolismClinical Pharmacology in Drug Development · 2023
18. QRFP receptor in GtoPdb v.2023.1IUPHAR/BPS Guide to Pharmacology CITE · 2023
19. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studiesThe Lancet · 2023
20. Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: Results from a phase 2b randomized placebo‐controlled trial (CAPTIVATE)Neurogastroenterology & Motility · 2023